3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
5
Rectal Neoplasms
2
Colonic Neoplasms
2
Cholangiocarcinoma
2
Adenocarcinoma Of Esophagus
2
Stomach Neoplasms
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Disease Progression
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Bile Duct Neoplasms
1
Advanced Rectal Cancer
1
Interventions
tivozanib
2
durvalumab
2
Specimen Handling
2
Magnetic Resonance Spectroscopy
2
Gemcitabine
2
Cisplatin
2
olaparib
1
atezolizumab
1
Stents
1
Oxaliplatin
1
Nivolumab
1
Leucovorin
1
Ipilimumab
1
Folfox protocol
1
Fluorouracil
1
CTLA-4 Antigen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Bile Duct Neoplasms
×
Folfox protocol
×
30 days
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts